1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 22,800 | 25,800 | 18.02. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Oculis Holding AG: Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities and Persons Closely Associated | 4 | GlobeNewswire (USA) | ||
| Di | Oculis Holding AG: Oculis Appoints Katie Kazem as Chief Legal Officer | 258 | GlobeNewswire (Europe) | ZUG, Switzerland, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Ms. Kazem brings extensive and global expertise in corporate governance and securities law, drawing on a distinguished track record as external legal... ► Artikel lesen | |
| OCULIS Aktie jetzt für 0€ handeln | |||||
| 06.01. | Oculis gains on FDA breakthrough therapy status for optic neuritis therapy | 7 | Seeking Alpha | ||
| 06.01. | Why Oculis Is Rising In Pre-market? | 3 | RTTNews | ||
| 06.01. | Oculis Holding AG: Oculis Announces U.S. FDA Breakthrough Therapy Designation Granted to Privosegtor for Treatment of Optic Neuritis | 641 | GlobeNewswire (Europe) | ZUG, Switzerland, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Breakthrough Therapy Designation granted to Privosegtor, a neuroprotective candidate, for the treatment of optic neuritis Privosegtor is advancing... ► Artikel lesen | |
| 09.12.25 | Oculis Holding AG: Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities | 12 | GlobeNewswire (USA) | ||
| 03.12.25 | Oculis Holding AG: Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities | 3 | GlobeNewswire (USA) | ||
| 28.11.25 | Oculis Holding AG: Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities | 2 | GlobeNewswire (USA) | ||
| 18.11.25 | Oculis Holding AG: Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities | 3 | GlobeNewswire (USA) | ||
| 11.11.25 | Oculis Holding AG Q3 Loss Declines | 8 | RTTNews | ||
| 10.11.25 | Oculis Holding GAAP EPS of CHF -0.32 | 6 | Seeking Alpha | ||
| 10.11.25 | Oculis Holding AG: Oculis Reports Q3 2025 Financial Results and Provides Company Update | 438 | GlobeNewswire (Europe) | ZUG, Switzerland, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Oculis accelerates its portfolio development with Privosegtor moving into the PIONEER pivotal program in Acute Optic Neuritis (AON) and Non-arteritic... ► Artikel lesen | |
| 10.11.25 | Oculis Holding AG - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 30.10.25 | Oculis Holding AG: Oculis Announces Oversubscribed $110 Million Financing to Accelerate Privosegtor Development | 402 | GlobeNewswire (Europe) | ZUG, Switzerland, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) ("Oculis" or the "Company"), a global biopharmaceutical company focused on breakthrough innovations to... ► Artikel lesen | |
| 29.10.25 | Oculis Holding AG - 6-K, Report of foreign issuer | 5 | SEC Filings | ||
| 14.10.25 | Oculis Holding AG: Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities | 8 | GlobeNewswire (USA) | ||
| 14.10.25 | Oculis Holding AG: Oculis to Spotlight Transformative Late-Stage Pipeline at Eyecelerator and AAO 2025 | 7 | GlobeNewswire (USA) | ||
| 08.10.25 | Oculis Holding AG: Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities | 2 | GlobeNewswire (USA) | ||
| 07.10.25 | Oculis stock price target raised to $36 from $33 at H.C. Wainwright | 2 | Investing.com | ||
| 06.10.25 | Oculis Holding AG - 6-K, Report of foreign issuer | 3 | SEC Filings |
1 2 Weiter >>
36 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 91,95 | +0,33 % | BioNTech-Rivale Moderna: Besser als erwartet - ist die Aktie jetzt ein Kauf? | Die US-amerikanische Biotech-Gesellschaft Moderna hat am heutigen Freitag die Zahlen für das abgelaufene vierte Quartal 2025 vorgelegt. Diese lagen deutlich über den Erwartungen. Von den Eckdaten kann... ► Artikel lesen | |
| EVOTEC | 6,198 | +2,14 % | Evotec Aktie: Der dicke Knoten könnte bald platzen - einsteigen? | Bei der Evotec Aktie bleibt es das bekannte Bild: seit November 2024 (!) scheitern regelmäßig die Versuche der Biotech-Aktie, sich stabil über der 200-Tage-Linie zu etablieren. Sieben Breakphasen über... ► Artikel lesen | |
| QIAGEN | 41,550 | +0,48 % | BERENBERG stuft QIAGEN NV auf 'Buy' | HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat das Kursziel für Qiagen von 46 auf 50 Euro angehoben und die Einstufung auf "Buy" belassen. Inmitten der Übernahmespekulationen liefere der... ► Artikel lesen | |
| BIOGEN | 164,75 | 0,00 % | Biogen auf dem Piper Sandler Symposium: Strategischer Fokus auf die Behandlung von Lupus | ||
| CRISPR THERAPEUTICS | 45,400 | 0,00 % | CRISPR Therapeutics AG: CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results | ZUG, Switzerland and BOSTON, Feb. 12, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today reported financial results for the fourth quarter and full year ended December 31, 2025. "As... ► Artikel lesen | |
| KUROS BIOSCIENCES | 27,820 | -0,50 % | KUROS BIOSCIENCES AG zeigt strukturelle Stärke | ||
| IDORSIA | 4,370 | +0,58 % | Idorsia Pharmaceuticals Ltd: Invitation to Idorsia's FY 2025 Financial Reporting webcast and conference call | Idorsia will publish its Full Year 2025 Financial Reporting on Thursday February 26, at 07:00 CET.
An investor webcast and conference call will be held to discuss the results on the same day.
Date:... ► Artikel lesen | |
| TELIX PHARMACEUTICALS | 5,292 | +1,26 % | Telix Submits European Marketing Authorization Application For TLX101-Px | CANBERA (dpa-AFX) - Telix Pharmaceuticals Limited (TLX) has submitted a marketing authorization
application in Europe for TLX101-Px, its glioma imaging candidate. The submission covers major... ► Artikel lesen | |
| AC IMMUNE | 2,225 | +0,23 % | AC Immune says partner J&J pauses enrollment in mid-stage trial for Alzheimer's drug | ||
| ZAI LAB LTD ADR | 16,900 | -1,17 % | ZAI LAB (09688): NOTICE OF BOARD ACTION AND DATE OF PUBLICATION OF 2025 ANNUAL RESULTS ANNOUNCEMENT | ||
| ARCTURUS THERAPEUTICS | 7,500 | +1,35 % | Arcturus Therapeutics Provides Interim Phase 2 Data for Cystic Fibrosis Program | ARCT-032 generally safe and well tolerated
Meaningful trends of clinical activity observed via high resolution CT scans
After only 28 days of treatment with ARCT-032 (10 mg), 4 out of 6 Class... ► Artikel lesen | |
| 3SBIO | 2,480 | +1,64 % | CMBI Expects 707 Drug Value Release to Drive 3SBIO Upside | ||
| AUTOLUS THERAPEUTICS | 1,340 | +1,52 % | H.C. Wainwright initiates Autolus stock coverage with buy rating | ||
| VTV THERAPEUTICS | 30,600 | +10,07 % | vTv Therapeutics Inc.: vTv Therapeutics and M42's IROS Announce Submission of Phase 2 Clinical Study Protocol for Cadisegliatin in Type 2 Diabetes to the United Arab Emirates Department of Health | HIGH POINT, N.C., Dec. 18, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company, today announced a Phase 2 clinical study protocol developed in collaboration... ► Artikel lesen | |
| MOONLAKE IMMUNOTHERAPEUTICS | 18,450 | 0,00 % | MoonLake Immunotherapeutics AG: MoonLake Announces FDA Fast Track Designation for Sonelokimab Palmoplantar Pustulosis (PPP) and Provides Details on Upcoming Investor Day | The Dermatology Division of the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to sonelokimab (SLK) in moderate-to-severe palmoplantar pustulosis (PPP) supported by positive... ► Artikel lesen |
OCULIS HOLDING AG gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 23,100 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu OCULIS HOLDING AG finden Sie auf Wallstreet Online.